clinical trial · NCT04817007
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb·phase2·active not recruiting·n = 216
MyelofibrosisBMS-986158RuxolitinibFedratinib
brief summary
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.
started
Mar 22, 2021
primary completion
May 31, 2026
completion
May 31, 2026
last updated
Sep 10, 2025
official title
A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol